Please login to the form below

Not currently logged in
Email:
Password:

Gilead Sciences in US investigation

Gilead Sciences is having its manufacturing and distribution practices investigated by the US Attorney's Office

Gilead Sciences has received a subpoena from the US Attorney's Office for the Northern District of California requesting documents related to the manufacture, and related quality and distribution practices of its HIV and hepatitis B drugs.

The subpoena involves the drugs Atripla (efavirenz tenofovir emtricitabine), Emtriva (emtricitabine), Hepsera (adefovir dipivoxil), Letairis (ambrisentan), Truvada (tenofovir emtricitabine), Viread (tenofovir) and its investigational fixed-dose combination of Truvada and Edurant (rilpivirine).

In a statement the company said it is cooperating with the civil and criminal investigation.

The case could take years to resolve and is likely to result in a substantial fine.

14th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics